<?xml version="1.0" encoding="utf-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd http://www.google.com/schemas/sitemap-news/0.9 http://www.google.com/schemas/sitemap-news/0.9/sitemap-news.xsd"><url><loc>https://www.pharmamanufacturing.com/industry-news/news/55409298/lonza-asimov-team-to-advance-in-vivo-lentiviral-vector-manufacturing</loc><news:news><news:publication><news:name>Pharma Manufacturing</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-02T15:35:23.000Z</news:publication_date><news:title>Lonza, Asimov team to advance in vivo lentiviral vector manufacturing</news:title></news:news></url><url><loc>https://www.pharmamanufacturing.com/industry-news/news/55409293/fresenius-takes-full-ownership-of-mabxience-biosimilars-platform</loc><news:news><news:publication><news:name>Pharma Manufacturing</news:name><news:language>en</news:language></news:publication><news:publication_date>2026-10-02T14:49:22.000Z</news:publication_date><news:title>Fresenius takes full ownership of mAbxience biosimilars platform</news:title></news:news></url></urlset>